Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma

Blood

Volumn 120, Issue 19, 2012, Pages 3997-4005

  Valleron, Wilfried ^a,b   Ysebaert, Loic ^a,c   Berquet, Laure ^a,b   Fataccioli, Virginie ^d   Quelen, Cathy ^a,b   Martin, Antoine ^e   Parrens, Marie ^f   Lamant, Laurence ^g   De Leval, Laurence ^h   Gisselbrecht, Christian ⁱ   Gaulard, Philippe ^d   Brousset, Pierre ^a,b,g  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CHU de Bobigny   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g CHU PURPAN   (France)

^h UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; MICRORNA; PREDNISONE; SMALL NUCLEOLAR RNA; STEROID; VINCRISTINE;

AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

EID: 84868605564     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-438135     Document Type: Article

References (43)

1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83-87.
2. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010; 115(5):1026-1036.
3. Lee Y, Uhm JE, Lee HY, et al. Clinical features and prognostic factors of patients with 'peripheral T cell lymphoma, unspecified'. Ann Hematol. 2009;88(2):111-119.
4. López-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9(8):849-855. (Pubitemid 28440443)
5. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2008;111(9):4463-4470.
6. Piccaluga PP, Agostinelli C, Gazzola A, et al. Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep. 2010;5(4):222-228.
7. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472-2479. (Pubitemid 46630624)
8. de Leval L, Bisig B, Thielen C, Boniver J, Gaulard P. Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol. 2009;72(2):125-143.
9. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226-1237.
10. Swerdlow S, Campo E, Harris NL, eds; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008.
11. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
12. Savage KJ, Harris NL, Vose JM, et al; International Peripheral T-Cell Lymphoma Project. ALKanaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 111(12):5496-5504.
13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838. (Pubitemid 40839735)
14. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer. 2006; 6(11):857-866. (Pubitemid 44629897)
15. Nellen W, Hammann C. Small RNAs: Analysis and Regulatory Functions. Berlin, Germany: Springer-Verlag; 2005.
16. Bachellerie JP, Cavaille J, Huttenhofer A. The expanding snoRNA world. Biochimie. 2002;84(8): 775-790. (Pubitemid 35363462)
17. Cavaillé J, Bachellerie JP. Processing of fibrillarin-associated snoRNAs from pre-mRNA introns: an exonucleolytic process exclusively directed by the common stem-box terminal structure. Biochimie. 1996;78(6):443-456. (Pubitemid 26360080)
18. Caffarelli E, Fatica A, Prislei S, De Gregorio E, Fragapane P, Bozzoni I. Processing of the intron-encoded U16 and U18 snoRNAs: the conserved C and D boxes control both the processing reaction and the stability of the mature snoRNA. EMBO J. 1996;15(5):1121-1131. (Pubitemid 26077841)
19. Kiss T, Filipowicz W. Exonucleolytic processing of small nucleolar RNAs from pre-mRNA introns. Genes Dev. 1995;9(11):1411-1424.
20. Mei YP, Liao JP, Shen JP, et al. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis. Oncogene. 2012;31(22):2794-2804.
21. Brameier M, Herwig A, Reinhardt R, Walter L, Gruber J. Human box C/D snoRNAs with miRNA like functions: expanding the range of regulatory RNAs. Nucleic Acids Res. 2011;39(2):675-686.
22. Dong XY, Guo P, Boyd J, et al. Implication of snoRNA U50 in human breast cancer. J Genet Genomics. 2009;36(8):447-454.
23. Dong XY, Rodriguez C, Guo P, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008;17(7):1031-1042. (Pubitemid 351426037)
24. Ender C, Krek A, Friedlander MR, et al. A human snoRNA with microRNA-like functions. Mol Cell. 2008;32(4):519-528.
25. Ge J, Rudnick DA, He J, et al. Dyskerin ablation in mouse liver inhibits rRNA processing and cell division. Mol Cell Biol. 2010;30(2):413-422.
26. Kishore S, Khanna A, Zhang ZY, et al. The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum Mol Genet. 2010;19(7):1153-1164.
27. Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science. 2006;311(5758):230-232. (Pubitemid 43108188)
28. Valleron W, Laprevotte E, Gautier EF, et al. Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia. 2012;26(9):2052-2060.
29. Vocanson M, Rozieres A, Hennino A, et al. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. J Allergy Clin Immunol. 2010;126(2):280-289, e281-e287.
30. Narsinh KH, Sun N, Sanchez-Freire V, et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J Clin Invest. 2011;121(3):1217-1221.
31. Cavaillé J, Seitz H, Paulsen M, Ferguson-Smith AC, Bachellerie JP. Identification of tandemly-repeated C/D snoRNA genes at the imprinted human 14q32 domain reminiscent of those at the Prader-Willi/Angelman syndrome region. Hum Mol Genet. 2002;11(13):1527-1538. (Pubitemid 34679253)
32. Scott MS, Avolio F, Ono M, Lamond AI, Barton GJ. Human miRNA precursors with box H/ACA snoRNA features. PLoS Comput Biol. 2009;5(9):e1000507.
33. Gallagher RC, Pils B, Albalwi M, Francke U. Evidence for the role of PWCR1/HBII-85 C/D box small nucleolar RNAs in Prader-Willi syndrome. Am J Hum Genet. 2002;71(3):669-678. (Pubitemid 34970140)
34. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106-113.
35. Lamant L, McCarthy K, d'Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic largecell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-4676.
36. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25(10):1560-1570. (Pubitemid 43361941)
37. Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol. 2006; 24(3):113-119. (Pubitemid 44483903)
38. Fornari A, Piva R, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol. 2009;27(4):161-170.
39. Dragon F, Gallagher JE, Compagnone-Post PA, et al. A large nucleolar U3 ribonucleoprotein required for 18S ribosomal RNA biogenesis. Nature. 2002;417(6892):967-970. (Pubitemid 34716875)
40. Bernstein KA, Gallagher JE, Mitchell BM, Granneman S, Baserga SJ. The small-subunit processome is a ribosome assembly intermediate. Eukaryot Cell. 2004;3(6):1619-1626. (Pubitemid 40025119)
41. Hu L, Wang J, Liu Y, et al. A small ribosomal subunit (SSU) processome component, the human U3 protein 14A (hUTP14A) binds p53 and promotes p53 degradation. J Biol Chem. 2011; 286(4):3119-3128.
42. Lamant L, McCarthy K, d'Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-4676.
43. Ono M, Scott MS, Yamada K, Avolio F, Barton GJ, Lamond AI. Identification of human miRNA precursors that resemble box C/D snoRNAs. Nucleic Acids Res. 2011;39(9):3879-3891.